证券日报网讯 12月12日晚间，皓元医药发布公告称，截至2025年12月11日，公司及子公司对外担保总 额为人民币73，242.19万元（含本次担保），全部为公司对全资或控股子公司提供的担保总额，占公司 2024年度经审计净资产及总资产的比例分别为25.45%、13.30%。此外，公司及子公司不存在逾期担保 和涉及诉讼担保的情形。 （文章来源：证券日报） ...

Core Viewpoint - *ST Sailong (002898.SZ) has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Rabeprazole, which is indicated for the treatment of bleeding gastric ulcers and duodenal ulcers when oral therapy is not suitable [1] Group 1 - The approval pertains to the injection formulation of Rabeprazole [1] - The drug is specifically aimed at treating conditions that cannot be managed with oral therapies [1]

Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Hunan Sailong Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Rulanzoprazole, which is intended for treating bleeding gastric and duodenal ulcers when oral therapy is not suitable [1] Group 1 - The approval notification number for Rulanzoprazole is 2025YS01099, and it is valid until December 10, 2030 [1] - Rulanzoprazole injection will enhance the company’s raw material drug product pipeline [1] - There is uncertainty regarding the production and sales situation, and the company will disclose information as progress occurs [1]

人福医药(600079.SH)发布公告，公司于2025年12月12日收到中国证券监督管理委员会湖北监管局下发 的《行政处罚事先告知书》(鄂处罚字〔2025〕8号)，依据《行政处罚事先告知书》载明的内容，根据 《上海证券交易所股票上市规则(2025年4月修订)》相关规定，公司股票将被实施其他风险警示。实施 后A股简称为ST人福。 公司股票将于2025年12月15日停牌1天，2025年12月16日起实施其他风险警示，实施其他风险警示后公 司股票将在风险警示板交易，股票价格的日涨跌幅限制为5%。 MACD金叉信号形成，这些股涨势不错！ ...

Group 1 - The core announcement is that Yongtai Technology's wholly-owned subsidiary, Binhai Meikang Pharmaceutical Co., Ltd., has received the drug registration certificate for Lidocaine and Prilocaine Cream from the National Medical Products Administration [2] Group 2 - The approval signifies a regulatory milestone for the company, potentially enhancing its product portfolio in the pharmaceutical sector [2] - This development may lead to increased market opportunities and revenue growth for Yongtai Technology in the future [2]

人福医药公告，公司于2025年12月12日收到中国证券监督管理委员会湖北监管局下发的《行政处罚事先 告知书》，依据相关法规，公司股票将被实施其他风险警示。公司股票将于2025年12月15日停牌1天， 并于2025年12月16日起实施其他风险警示，实施后A股简称将变更为"ST人福"，股票价格的日涨跌幅限 制为5%。 ...

| | | | | 用泰港台版登錄份 | 机构专用 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 2025-12-12 | 恒瑞医药 | 証券代码 ---- 600276 | 成交价(元) 成交金额(万元) 咸交量(*) 买入营业部 63.28 358.16 5.66 | | | 卖出营业部 | 是否为专场 | Ka | 12月12日，恒瑞医药大宗交易成交5.66万股，成交额358.16万元，占当日总成交额的0.18%，成交价 63.28元，较市场收盘价63.28元持平。 ...

从资金流向上来看，当日化学制药板块主力资金净流出8.32亿元，游资资金净流入1.42亿元，散户资金 净流入6.9亿元。化学制药板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，12月12日化学制药板块较上一交易日下跌0.44%，退市苏吴领跌。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。化学制药板块个股涨跌见下表： ...

Core Viewpoint - Laimei Pharmaceutical reported a decrease in the number of shareholders and a decline in financial performance for the third quarter, indicating potential challenges for the company moving forward [2] Shareholder Information - As of December 10, the number of shareholders for Laimei Pharmaceutical was 31,490, a decrease of 1,813 from the previous period (November 30), representing a month-on-month decline of 5.44% [2] Stock Performance - The closing price of Laimei Pharmaceutical was 4.86 yuan, reflecting an increase of 1.67%. However, since the concentration of shares began, the stock price has cumulatively decreased by 5.63%, with 4 days of increases and 6 days of decreases during this period [2] Financial Performance - For the first three quarters, Laimei Pharmaceutical achieved a total operating revenue of 581 million yuan, a year-on-year decrease of 4.06%. The net profit was -45.9172 million yuan, representing a year-on-year decline of 73.82%. The basic earnings per share were -0.0435 yuan [2]

Core Viewpoint - The chairman of Jincheng Pharmaceutical, Zhao Yeqing, has resigned following a formal penalty from the China Securities Regulatory Commission (CSRC) for stock manipulation, which included a fine of 1.5 million yuan and a four-year market ban [1][6]. Summary by Sections Announcement of Resignation and Penalty - Zhao Yeqing submitted his resignation as chairman and other board positions due to personal reasons, coinciding with the issuance of the CSRC's administrative penalty decision [1][7]. - The penalty includes a fine of 1.5 million yuan for Zhao Yeqing, with additional fines for co-conspirators Wang Zhen and Liu Feng, totaling 3 million yuan [6]. Details of Stock Manipulation - From August 18, 2017, to February 10, 2020, Zhao Yeqing, along with Wang Zhen and Liu Feng, manipulated Jincheng Pharmaceutical's stock using 104 accounts over nearly 600 trading days, resulting in a loss of approximately 7.39 million yuan [2][4]. - The account group held an average of 18.58 million shares, representing 5.68% of the company's circulating shares, with a peak holding of 32.09 million shares, or 9.04% [4]. Impact on Stock Price - During the manipulation period, the account group exhibited significant buying interest, accounting for 17.29% of the market's buy orders and 23.02% of the market's trading volume at certain times, leading to a stock price increase of 21.30% compared to a 2.90% increase in the ChiNext index [4][5]. Evidence and Regulatory Findings - The CSRC found sufficient evidence of coordinated manipulation, including transaction records and witness testimonies, and rejected the defendants' claims of lack of intent and other defenses [6][9]. - The investigation and hearing process lasted over a year, with the CSRC's decision marking the conclusion of the investigation into Zhao Yeqing's actions [9].